Advanced search
Publication Cover
Psoriasis: Targets and Therapy Volume 10, 2020 - Issue
Submit an article Journal homepage
102
Views
2
CrossRef citations to date
0
Altmetric
Case Report

CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab

Alessio Gambardella1 Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
,
Gaetano Licata1 Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, ItalyCorrespondence[email protected]
,
Giulia Calabrese1 Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
,
Alina De Rosa1 Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
,
Francesca Pagliuca2 Division of Pathology, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
,
Roberto Alfano3 Department of Anesthesiology, Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy
&
Giuseppe Argenziano1 Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
 show all
Pages 57-60 | Published online: 27 Nov 2020

Figures & data

Figure 1 (A and B) Moderate-to-severe psoriasis, with a Psoriasis Area and Severity Index (PASI) score of 16, body surface area (BSA) score of 12 and Dermatology Life Quality Index (DLQI) score of 18 prior to treatment with biological therapy. (C and D) Complete clinical response after 16 weeks of secukinumab.

Figure 1 (A and B) Moderate-to-severe psoriasis, with a Psoriasis Area and Severity Index (PASI) score of 16, body surface area (BSA) score of 12 and Dermatology Life Quality Index (DLQI) score of 18 prior to treatment with biological therapy. (C and D) Complete clinical response after 16 weeks of secukinumab.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.